<DOC>
	<DOCNO>NCT00004223</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness docetaxel gemcitabine treat patient progressive regional metastatic bladder cancer .</brief_summary>
	<brief_title>Docetaxel Gemcitabine Treating Patients With Progressive Regional Metastatic Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate patient progressive regional metastatic transitional cell carcinoma urothelium failure 1 prior systemic regimen treat docetaxel gemcitabine . II . Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive docetaxel IV 1 hour follow gemcitabine IV 30 minute day 1 8 . For patient complete partial response stable disease 3 week , treatment repeat every 3 week maximum 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month year 2 , every 6 month year 5 , annually thereafter disease progression . PROJECTED ACCRUAL : A total 22-45 patient accrue study 18-21 month .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven progressive regional metastatic transitional cell carcinoma urothelium mixed histology contain component transitional cell carcinoma Failure 1 prior chemotherapy regimen metastatic disease adjuvant neoadjuvant setting ( contain taxane gemcitabine ) Bidimensionally measurable disease No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 75,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT great 2.5 time upper limit normal ( ULN ) alkaline phosphatase normal OR Alkaline phosphatase great 4 time ULN SGOT normal OR SGOT le 1.5 time ULN AND alkaline phosphatase less 2.5 time ULN Renal : Creatinine great 1.8 mg/dL Cardiovascular : No American Heart Association class III IV heart disease No uncontrolled congestive heart failure No severe cardiac arrhythmia Neurologic : No sensory neuropathy grade 3 4 No prior peripheral neuropathy grade 2 bad Other : No active unresolved infection treat parenteral antibiotic within past 7 day No malignancy within past 5 year except : Curatively treat basal squamous cell skin cancer carcinoma situ cervix Clinically unsuspected , organ confine prostate cancer find cystoprostatectomy Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior systemic biologic response modifier therapy Prior intravesical BCG allow Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 4 week since prior major surgery recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>stage III bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
</DOC>